Relevance of pheno- and genotyping in clinical drug development

International Journal of Clinical Pharmacology and Therapeutics

Volumn 36, Issue 11, 1998, Pages 607-612

  Zuhlsdorf M T ^a,b  

^a Institute of Clinical Pharmacology   (Germany)

^b Institute of Clinical Pharmacology   (Germany)

Author keywords

Drug development; Pharmacoanthropology; Pharmacogenetics; Pharmacogenomics; Polymorphism

Indexed keywords

DRUG METABOLIZING ENZYME; XENOBIOTIC AGENT;

BLOOD LEVEL; CONFERENCE PAPER; DRUG DEVELOPMENT; DRUG METABOLISM; DRUG RESPONSE; DRUG SCREENING; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOME; GENOTYPE; MOLECULAR BIOLOGY; PHARMACOGENETICS; PHENOTYPE;

DECISION TREES; DRUG DESIGN; DRUG EVALUATION; GENOTYPE; HUMANS; PHARMACOGENETICS; PHARMACOKINETICS; PHARMACOLOGY; PHENOTYPE; POLYMORPHISM, GENETIC; XENOBIOTICS;

EID: 0031742831     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Ball S 1997 Evaluating the role of polymorphic drug-metabolising enzymes in the pharmaceutical industry - impact on drug candidate selection and advancement. IBC's Third Annual Conference on Pharmacogenetics
2. Bernstam VA 1992 Handbook of Gene Level Diagnostics in Clinical Practice. CRC Press, Boca Raton
3. Bertilsson L, Dahl ML 1996 Polymorphic drug oxidation - relevance to the treatment of psychiatric disorders. CNS Drugs 5: 200-223
4. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA 1991 Debrisoquine/sparteine hydroxylation genotype and phenotype: Analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 10: 545-558
5. Chen SQ, Chou WH, Blouin RA, Mao ZP, Humphries LL, Meek C, Neill JR, Martin WL, Hays LR, Wedlund PJ 1996 The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry. Clin Pharm Ther 60: 522-534
6. Cholerton S, Daly AK Idle JR 1992 The role of individual cytochromes P450 in drug metabolism and clinical response. TIPS 13: 434-439
7. Daly AK 1995 Molecular basis of polymorphic drug metabolism. J Mol Med 73: 539-553
8. Daly AK, Cholerton S, Armstrong M, Idle JR 1994 Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility. Environ Health Perspect 102: 55-61
9. Engel G, Hofmann U, Heidemann H, Cosme J, Eichelbaum M 1996 Antipyrine as a probe for human oxidative drug metabolism - identification of the cytochrome P450 enzymes catalysing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther 59: 613-623
10. Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA 1997 Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolising enzymes. Clin Pharmacol Ther 62: 365-376
11. Gonzalez FJ, Idle JR 1994 Pharmacogenetic phenotyping and genotyping - Present status and future potential. Clin Pharmacokinet 26, 59-70
12. Inaba T, Nebert DW, Burchell B, Watkins PB, Goldstein JA, Bertilsson L, Tucker GT 1995. Pharmacogenetics in clinical pharmacology and toxicology. Can J Physiol Pharmacol 73: 331-338
13. Kivistö KT, Kroemer HK 1997 Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 37:40S-48S
14. Park BK, Kitteringham NR 1988 Relevance and means of assessing induction and inhibition of drug metabolism in man. Prog Drug Metab 11: 1-60
15. Silber 1997 Pharmacogenetics and drug-metabolising enzymes. IBC's Third Annual Conference on Pharmacogenetics